Journal
CANCER COMMUNICATIONS
Volume 41, Issue 9, Pages 830-850Publisher
WILEY
DOI: 10.1002/cac2.12183
Keywords
antiangiogenesis; bevacizumab; cancer; combination therapy; immune-checkpoint inhibitor; immunotherapy; vascular endothelial growth factor
Categories
Funding
- National Key Research and Development Program [2017YFSF090107]
- National Natural Science Foundation of China [82072996, 81874131]
- Hubei Province Natural Science Funds for Distinguished Young Scholar [2017CFA062]
- Innovative research team of high-level local universities in Shanghai [ZLCX20180500]
Ask authors/readers for more resources
Cancer immunotherapy has had significant success in recent years, but still faces challenges such as limited patient response. Combining immunotherapy with other therapies or antiangiogenic agents may help overcome resistance to monotherapy. Understanding the interactions between antiangiogenic agents and immunotherapy is crucial for improving treatment outcomes in solid tumors.
Cancer immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized oncology. However, only a limited number of patients benefit from immunotherapy, and some cancers that initially respond to immunotherapy can ultimately relapse and progress. Thus, some studies have investigated combining immunotherapy with other therapies to overcome resistance to monotherapy. Recently, multiple preclinical and clinical studies have shown that tumor vasculature is a determinant of whether immunotherapy will elicit an antitumor response; thus, vascular targeting may be a promising strategy to improve cancer immunotherapy outcomes. A successful antitumor immune response requires an intact Cancer-Immunity Cycle, including T cell priming and activation, immune cell recruitment, and recognition and killing of cancer cells. Angiogenic inducers, especially vascular endothelial growth factor (VEGF), can interfere with activation, infiltration, and function of T cells, thus breaking the Cancer-Immunity Cycle. Together with immunostimulation-regulated tumor vessel remodeling, VEGF-mediated immunosuppression provides a solid therapeutic rationale for combining immunotherapy with antiangiogenic agents to treat solid tumors. Following the successes of recent landmark phase III clinical trials, therapies combining immune checkpoint inhibitors (ICIs) with antiangiogenic agents have become first-line treatments for multiple solid tumors, whereas the efficacy of such combinations in other solid tumors remains to be validated in ongoing studies. In this review, we discussed synergies between antiangiogenic agents and cancer immunotherapy based on results from preclinical and translational studies. Then, we discussed recent progress in randomized clinical trials. ICI-containing combinations were the focus of this review because of their recent successes, but combinations containing other immunotherapies were also discussed. Finally, we attempted to define critical challenges in combining ICIs with antiangiogenic agents to promote coordination and stimulate collaboration within the research community.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available